These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25965709)

  • 1. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.
    O'Donoghue ML; Glaser R; Aylward PE; Cavender MA; Crisp A; Fox KA; Laws I; Lopez-Sendon JL; Steg PG; Theroux P; Sabatine MS; Morrow DA
    Am Heart J; 2015 May; 169(5):622-630.e6. PubMed ID: 25965709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
    O'Donoghue ML; Glaser R; Cavender MA; Aylward PE; Bonaca MP; Budaj A; Davies RY; Dellborg M; Fox KA; Gutierrez JA; Hamm C; Kiss RG; Kovar F; Kuder JF; Im KA; Lepore JJ; Lopez-Sendon JL; Ophuis TO; Parkhomenko A; Shannon JB; Spinar J; Tanguay JF; Ruda M; Steg PG; Theroux P; Wiviott SD; Laws I; Sabatine MS; Morrow DA;
    JAMA; 2016 Apr; 315(15):1591-9. PubMed ID: 27043082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale.
    Melloni C; Sprecher DL; Sarov-Blat L; Patel MR; Heitner JF; Hamm CW; Aylward P; Tanguay JF; DeWinter RJ; Marber MS; Lerman A; Hasselblad V; Granger CB; Newby LK
    Am Heart J; 2012 Nov; 164(5):646-653.e3. PubMed ID: 23137494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study.
    Ostenfeld T; Krishen A; Lai RY; Bullman J; Baines AJ; Green J; Anand P; Kelly M
    Eur J Pain; 2013 Jul; 17(6):844-57. PubMed ID: 23239139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
    Watz H; Barnacle H; Hartley BF; Chan R
    Lancet Respir Med; 2014 Jan; 2(1):63-72. PubMed ID: 24461903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
    Newby LK; Marber MS; Melloni C; Sarov-Blat L; Aberle LH; Aylward PE; Cai G; de Winter RJ; Hamm CW; Heitner JF; Kim R; Lerman A; Patel MR; Tanguay JF; Lepore JJ; Al-Khalidi HR; Sprecher DL; Granger CB;
    Lancet; 2014 Sep; 384(9949):1187-95. PubMed ID: 24930728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod.
    Kragholm K; Newby LK; Melloni C
    Drug Des Devel Ther; 2015; 9():4279-86. PubMed ID: 26273189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.
    Inamdar A; Merlo-Pich E; Gee M; Makumi C; Mistry P; Robertson J; Steinberg E; Zamuner S; Learned S; Alexander R; Ratti E
    J Psychopharmacol; 2014 Jun; 28(6):570-81. PubMed ID: 24699061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
    Bentley-Lewis R; Aguilar D; Riddle MC; Claggett B; Diaz R; Dickstein K; Gerstein HC; Johnston P; Køber LV; Lawson F; Lewis EF; Maggioni AP; McMurray JJ; Ping L; Probstfield JL; Solomon SD; Tardif JC; Wu Y; Pfeffer MA;
    Am Heart J; 2015 May; 169(5):631-638.e7. PubMed ID: 25965710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled trial of the analgesic efficacy and safety of the p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain from lumbosacral radiculopathy.
    Ostenfeld T; Krishen A; Lai RY; Bullman J; Green J; Anand P; Scholz J; Kelly M
    Clin J Pain; 2015 Apr; 31(4):283-93. PubMed ID: 25751578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial.
    Cavender MA; O'Donoghue ML; Abbate A; Aylward P; Fox KA; Glaser RX; Park JG; Lopez-Sendon J; Steg PG; Sabatine MS; Morrow DA
    Am Heart J; 2022 Jan; 243():147-157. PubMed ID: 34508693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.
    Elkhawad M; Rudd JH; Sarov-Blat L; Cai G; Wells R; Davies LC; Collier DJ; Marber MS; Choudhury RP; Fayad ZA; Tawakol A; Gleeson FV; Lepore JJ; Davis B; Willette RN; Wilkinson IB; Sprecher DL; Cheriyan J
    JACC Cardiovasc Imaging; 2012 Sep; 5(9):911-22. PubMed ID: 22974804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils.
    Marks-Konczalik J; Costa M; Robertson J; McKie E; Yang S; Pascoe S
    Respir Med; 2015 Jul; 109(7):860-9. PubMed ID: 26033641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
    Fisk M; Cheriyan J; Mohan D; Forman J; Mäki-Petäjä KM; McEniery CM; Fuld J; Rudd JHF; Hopkinson NS; Lomas DA; Cockcroft JR; Tal-Singer R; Polkey MI; Wilkinson IB
    PLoS One; 2018; 13(3):e0194197. PubMed ID: 29566026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Anti-Inflammatory Medications in Patients With Coronary Artery Disease: A Focus on Losmapimod.
    Tun B; Frishman WH
    Cardiol Rev; 2018; 26(3):152-156. PubMed ID: 29045288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
    O'Donoghue ML; Braunwald E; White HD; Serruys P; Steg PG; Hochman J; Maggioni AP; Bode C; Weaver D; Johnson JL; Cicconetti G; Lukas MA; Tarka E; Cannon CP
    Am Heart J; 2011 Oct; 162(4):613-619.e1. PubMed ID: 21982651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C; Newby LK
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Skene A; McCabe CH; Braunwald E;
    Am Heart J; 2006 Jun; 151(6):1186.e1-9. PubMed ID: 16781216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, pharmacokinetics, and pharmacodynamics of losmapimod in healthy Japanese volunteers.
    Ino H; Takahashi N; Terao T; Igarashi H; Sarai N
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):262-9. PubMed ID: 27136906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.